Hence, this study determined the diagnostic performance of traditional tests (IOTA-LR2 and CA-125) and a multivariate index assay (MIA2G) in evaluating patients with early-stage ovarian cancer. This evidence concerns the gene MUC16 and ovarian carcinoma.